

Funkčný test stanovenia HIT prietokovou cytometriou


Škorňová I. ¹, Vážanová A. ¹, Lauko V. ², Staško J. ¹

¹Národné centrum hemostázy a trombózy,
Klinika hematológie a transfuziológie JLF UK a UNM, Martin
²NÚSCH, a.s. Bratislava



Úvod

- Heparínom indukovaná trombocytopénia (**HIT**) – je protilátkami sprostredkovaná **nežiadúca** reakcia po podaní heparínu.
- **Protilátky** sa môžu vytvoriť až po expozícii heparínu a **sú namierené** proti doštičkovému faktoru 4 (**PF4**);
- Komplex **heparín-PF4-protilátka** sa viaže na doštičky cez FcγRII; spôsobuje ich aktiváciu a agregáciu (uvoľňujú mikropartikuly; zvýšená tvorba trombínu);
- Spôsobuje **trombocytopéniu**, arteriálnu alebo žilovú **trombózu**;
- Prevalencia je približne **0,5–5 %** heparinizovaných pacientov.



I. History and Physical Examination: Evaluating the Clinical Probability of HIT

A. Features of the history and physical examination that support a diagnosis of HIT

| Feature | Comments |
|---|---|
| Fall in platelet count $\geq 50\%$ | From highest platelet count after heparin exposure; platelet count fall is 30–50% in 10% of cases |
| Fall in platelet count begins 5–14 days after immunizing heparin exposure | Heparin administered during or soon after surgery is more likely to be immunizing |
| Fall in platelet count begins within 24 hours after heparin exposure | May occur in patients with previous heparin exposure within last 100 days |
| Nadir platelet count $\geq 20 \times 10^9/L$ | Nadir may exceed lower limit of normal range (i.e. $150 \times 10^9/L$) in patients with high baseline platelet counts. May be $< 20 \times 10^9/L$ in cases associated with DIC |
| Venous or arterial thrombosis | Occurring ≥ 5 days after heparin exposure and up to 30 days after heparin cessation |
| Skin necrosis | At subcutaneous heparin injection sites |
| Anaphylactoid reaction | Within 30 minutes after intravenous heparin bolus or subcutaneous injection |
| Absence of alternative causes of thrombocytopenia | Such as infection, other medications known to cause thrombocytopenia, cardiopulmonary bypass within previous 96 hours, intra-aortic balloon pump, extracorporeal membrane oxygenation, etc. |
| Absence of petechiae and other mucocutaneous bleeding | Adrenal hemorrhage secondary to adrenal vein thrombosis may occur in association with HIT |

B. The 4Ts: A clinical probability scoring system

| 4Ts | 2 Points | 1 Point | 0 Points |
|--|---|--|--|
| T hrombocytopenia | Platelet count fall > 50% and platelet nadir $\geq 20 \times 10^9/L$ | Platelet count fall 30–50% or platelet nadir $10-19 \times 10^9/L$ | Platelet count fall < 30% or platelet nadir $< 10 \times 10^9/L$ |
| T iming of platelet count fall | Clear onset between days 5–14 or platelet fall ≤ 1 day (prior heparin exposure within 30 days) | Consistent with days 5–14 fall, but not clear (e.g. missing platelet counts) or onset after day 14 or fall ≤ 1 day (prior heparin exposure 30–100 days ago) | Platelet count fall ≤ 4 days without recent exposure |
| T hrombosis or other sequelae | New thrombosis (confirmed); skin necrosis at heparin injection sites; anaphylactoid reaction after IV heparin bolus | Progressive or recurrent thrombosis; Non-necrotizing (erythematous) skin lesions; Suspected thrombosis (not confirmed) | None |
| o ther causes of thrombocytopenia | None apparent | Possible | Definite |

High probability (6–8 points), intermediate probability (4–5 points), low probability (≤ 3 points).

Adapted from Lo et al., *J Thromb Haemost* 2006;4:759. The 4Ts has not been compared with intuition-based diagnosis. It may be used as a guide for clinicians but should not substitute for clinical judgment. In a meta-analysis, the negative predictive value of a low probability 4T score was 99.8% (i.e. a low probability score reliably excludes HIT). The positive predictive values of intermediate and high probability scores were 14% and 64%, respectively (Cuker et al., *Blood* 2012;120:4160).


II. Laboratory Diagnosis

| Assay category | Mechanism | Examples | Sensitivity | Specificity | Comments |
|----------------|--|--|-------------|-------------|--|
| Immunologic | Detects antibodies against PF4/heparin, regardless of their capacity to activate platelets | <ol style="list-style-type: none"> 1. Polyspecific ELISA 2. IgG-specific ELISA 3. PaGIA | >95% | 50–89% | OD of ELISA result correlates with clinical probability of HIT and odds of a positive functional assay |
| Functional | Detects antibodies that induce heparin-dependent platelet activation | <ol style="list-style-type: none"> 1. SRA 2. HIPA | 90–98% | 90–95% | Not widely available; requires referral to a reference laboratory |

PF4, platelet factor 4; PaGIA, particle gel immunoassay; OD, optical density; SRA, serotonin release assay; HIPA, heparin-induced platelet activation assay.


III. Diagnostic and Initial Treatment Algorithm

Adapted from Cuker et al., *Blood* 2012;119:2209. OD, optical density.



Metóda

- a) imunologický test **ID-PaGIA Heparin/PF4** (particle gel immunoassay);
- Imunologický test je založený na reakcii partikul a príslušnej protilátky v sére pacienta metódou stĺpcovej aglutinácie;
- Sérum sa inkubuje so špecifickými časticami. Po centrifugácii gélu sa na častice naviažu protilátky proti komplexu heparín / PF4;



Metóda

- b) funkčný test – kit HITAlert;
- Inkubácia PRP (trombocytov darcu) so sérom pacienta bez, s nízkou a vysokou dávkou heparínu
- Stanovenie aktivovaných doštičiek darcu (CD41+; Annexin V+). Annexin V rozpoznáva fosfatidylserín na povrchu aktivovaných doštičiek





Cieľ

- Cieľom práce bolo poukázať na **výhody, úskalia** a možnosti aplikácie funkčného testu HIT Alert pomocou prietokovej cytometrie.


Výsledky

- Analýzou **14 vzoriek** pacientov s podozrením HIT imunologickým testom **ID-PaGIA Heparin/PF4** sme dostali 13 pozitívnych výsledkov.
- Ďalším testovaním týchto vzoriek prietokovou cytometriou-kitom **HITAlert** malo **7 vzoriek** pozitívny a 6 vzoriek negatívny výsledok.


Analýza



Negatívna kontrola



Pozitívna kontrola






Kritériá interpretácie

HIT negat. HIT pozit.

- I. < 5 % < 5 %
- II. 80-100 % 80-100 %
- III. < 5 % aktivácia menej ako polovica vzorky IV
- IV. < 8 % > 8 %
- V. < 5 % aktivácia menej ako polovica vzorky IV

Vyšetrovaná vzorka:




Výsledok testu: NEGATÍVNY


Negatívna kontrola

Pozitívna kontrola

M I. PRP+ hep - PE posit platelets



M II. PRP+ Ca - PE posit platelets




Kritériá interpretácie


- **HIT negat. HIT pozit.**
- **I. < 5 % < 5 %**
- **II. 80-100 % 80-100 %**
- **III. < 5 % aktivácia menej ako polovica vzorky IV**
- **IV. < 8 % > 8 %**
- **V. < 5 % aktivácia menej ako polovica vzorky IV**

Vyšetovaná vzorka:


M III. PRP+ serum - PE posit platelets



M IV. PRP+serum+ hep - PE posit platelets



M V. PRP+serum+ exc. hep - PE posit platelets



Výsledok testu: POZITÍVNY

Záver

- Na základe našich doterajších skúseností aplikáciou funkčného testu stanovenia HIT pomocou prietokovej cytometrie môžeme povedať, že metóda má svoje:
- **výhody** (CE/IVD **funkčný** test, relatívne **krátky čas** analýzy- 110 minút, **nerádioaktívny**, vysoká **senzitivita a špecificita**)
- **úskalia** (vyžaduje **darčovské doštičky**, **špecializované pracoviská** s odbornou znalosťou a prístrojovým vybavením prietokovej cytometrie).

Pod'akovanie

- Táto práca bola podporená projektami:
- APVV – 16-0020;
- Vega 1/0168/16, Vega 1/0187/17;
- Centra excelentnosti pre perinatologický výskum (CEPV II, ITMS 26220120036);
- Centra excelentnosti pre výskum v personalizovanej terapii (CEVYPET).